Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional based on individual patient circumstances, current clinical guidelines, and sound medical judgment. The information provided herein is subject to change as new evidence emerges.

Antiphospholipid Syndrome

Overview

• Definition: Antiphospholipid Syndrome (APS) is a systemic autoimmune disorder characterized by recurrent arterial or venous thrombosis and/or pregnancy morbidity, in the persistent presence of antiphospholipid antibodies (aPL). It is defined by specific clinical and laboratory criteria.
• Epidemiology:
  • Prevalence: Estimated to affect 40-50 per 100,000 individuals in the general population.
  • Incidence: Approximately 2-5 new cases per 100,000 person-years.
  • Demographics: Predominantly affects women (female-to-male ratio of 3-5:1), especially those of childbearing age, but can occur at any age. The mean age of diagnosis is typically in the 30s-40s.
  • A significant proportion of patients with Systemic Lupus Erythematosus (SLE) (20-40%) have aPL, and about 10-15% of SLE patients will develop APS.
• Classification:
  • Primary APS: Occurs in the absence of any other underlying autoimmune disease.
  • Secondary APS: Occurs in conjunction with another autoimmune disease, most commonly Systemic Lupus Erythematosus (SLE).
  • Catastrophic Antiphospholipid Syndrome (CAPS): A rare, life-threatening variant characterized by widespread microvascular thrombosis leading to multi-organ failure over a short period (typically days to weeks).

Pathophysiology

• Mechanism: The exact pathophysiological mechanisms are complex and not fully understood, but involve the binding of pathogenic antiphospholipid antibodies (aPL) to phospholipid-binding proteins (primarily β2-glycoprotein I, but also prothrombin and annexin A5) expressed on various cell surfaces. This binding leads to a prothrombotic state through multiple pathways:
  1. Endothelial Cell Activation: aPL bind to β2GPI on endothelial cells, leading to increased expression of adhesion molecules (e.g., ICAM-1, VCAM-1, E-selectin), tissue factor (TF), and von Willebrand factor (vWF), and decreased production of prostacyclin and nitric oxide. This promotes a procoagulant, pro-inflammatory phenotype.
  2. Platelet Activation: aPL binding to platelets and/or platelet-bound β2GPI can activate platelets, leading to aggregation and thrombus formation.
  3. Monocyte Activation: aPL induce monocytes to express tissue factor, further contributing to thrombus formation.
  4. Complement Activation: aPL activate the complement cascade, particularly C3 and C5, leading to the generation of pro-inflammatory and procoagulant molecules (e.g., C5a, membrane attack complex). This is thought to be particularly important in pregnancy morbidity and CAPS.
  5. Coagulation Cascade Interference: Lupus anticoagulant (LA) antibodies directly interfere with phospholipid-dependent coagulation reactions, leading to paradoxical prolongation of clotting times in vitro but a prothrombotic state in vivo.
  6. Impaired Fibrinolysis: aPL may impair fibrinolysis by interfering with plasminogen activators and inhibitors.
• Risk Factors:
  • Genetic Predisposition: Certain HLA haplotypes (e.g., HLA-DR4, HLA-DRw53) may confer increased susceptibility.
  • Infections: Viral (e.g., HIV, hepatitis C, parvovirus B19) and bacterial infections (e.g., syphilis, Lyme disease) can induce transient aPL, but rarely cause thrombotic events unless underlying APS is present.
  • Medications: Certain drugs (e.g., chlorpromazine, procainamide, hydralazine, quinine) can induce aPL, though clinical thrombosis is rare.
  • Surgery/Trauma: Immobilization, surgery, or trauma can precipitate thrombosis in aPL carriers.
  • Malignancy: Increased risk of thrombosis in cancer patients, and some may also have aPL.
  • Cardiovascular Risk Factors: Traditional risk factors like hypertension, hyperlipidemia, diabetes, smoking, and obesity can synergize with aPL to increase thrombotic risk.
  • Estrogen-containing Contraceptives/Hormone Replacement Therapy: Exogenous estrogen is a significant thrombotic risk factor in aPL carriers.
  • Pregnancy: The procoagulant state of pregnancy further increases thrombotic risk.
  • Other Autoimmune Diseases: Especially SLE.
• Protective Factors: No well-established intrinsic protective factors against developing APS. However, appropriate primary and secondary prophylactic antithrombotic therapy is crucial in preventing thrombotic events.

Clinical Presentation

Signs and Symptoms

• Cardinal Features (Sydney Classification Criteria, 2006 update):
  • Vascular Thrombosis: One or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or organ. Thrombosis must be objectively confirmed by imaging, Doppler studies, or histopathology (without significant inflammation in the vessel wall).
    • Venous Thrombosis: Deep vein thrombosis (DVT) of lower extremities (most common), pulmonary embolism (PE), superficial thrombophlebitis, cerebral venous sinus thrombosis, Budd-Chiari syndrome.
    • Arterial Thrombosis: Ischemic stroke, transient ischemic attack (TIA), myocardial infarction, peripheral arterial occlusion (e.g., digital ischemia), mesenteric ischemia.
    • Small Vessel Thrombosis: Livedo reticularis, skin ulcers, adrenal hemorrhage.
  • Pregnancy Morbidity:
    • One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation.
    • One or more premature births of a morphologically normal neonate before the 34th week of gestation due to eclampsia, severe preeclampsia, or recognized features of placental insufficiency.
    • Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomical or hormonal causes and paternal and maternal chromosomal causes excluded.
• Early Signs: Often asymptomatic until a thrombotic event or pregnancy loss occurs. Recurrent severe headaches can be an early non-specific symptom.
• Advanced Signs:
  • Recurrent Thrombosis: Despite adequate anticoagulation.
  • Chronic Complications: Post-thrombotic syndrome (chronic leg pain, swelling after DVT), pulmonary hypertension (due to recurrent PE), chronic kidney disease (due to renal microthrombosis), avascular necrosis of bone.
  • Neuropsychiatric Manifestations: Cognitive dysfunction, migraine, chorea, transverse myelitis, seizures, multiple sclerosis-like syndrome.
• Atypical/Non-criteria Presentations:
  • Hematological: Thrombocytopenia (mild to moderate, common), hemolytic anemia.
  • Cardiac: Valvular heart disease (Libman-Sacks endocarditis, valvular thickening/regurgitation, particularly mitral and aortic), myocardial dysfunction.
  • Renal: APS nephropathy (renal artery stenosis, microangiopathy, glomerulopathy).
  • Dermatological: Livedo reticularis, skin ulcers, livedo racemosa, pseudovasculitis.
  • Neurological: Transverse myelitis, chorea, seizures, Guillain-Barré syndrome.
  • Ocular: Retinal vascular occlusion (arterial or venous), amaurosis fugax.
  • Adrenal: Adrenal infarction/hemorrhage leading to Addisonian crisis.

Physical Examination

• Inspection:
  • Dermatological: Livedo reticularis (a mottled, lacelike reddish-blue discoloration of the skin, typically on the extremities), livedo racemosa (a more broken, irregular pattern, often indicative of deeper vascular involvement), digital ischemia, skin ulcers, gangrene.
  • Neurological: Evidence of prior stroke (hemiparesis, facial droop), chorea (involuntary, jerky movements), visual field deficits.
  • Vascular: Unilateral leg swelling, erythema, tenderness (suggesting DVT).
• Palpation:
  • Vascular: Assessment of pulses for arterial occlusion. Tenderness and warmth in affected limbs for DVT.
  • Cardiac: Murmurs consistent with valvular disease.
• Special Tests:
  • Neurological examination (mini-mental state exam, cranial nerve assessment, motor/sensory testing) to assess for neurological involvement.
  • Funduscopic examination for retinal vascular changes.

Diagnostic Approach

History Taking

• Key Questions:
  • Thrombotic History: Detailed history of any arterial or venous thrombotic events (site, type, objective confirmation, circumstances, recurrence, age at first event). Unprovoked events, unusual sites (e.g., mesenteric, renal veins, cerebral sinuses), and young age at onset are highly suggestive.
  • Pregnancy History: Number of pregnancies, live births, miscarriages (gestational age), stillbirths, preeclampsia/eclampsia, placental abruption, fetal growth restriction.
  • Medication History: Use of oral contraceptives, hormone replacement therapy, drugs that can induce aPL.
  • Smoking History: Current or past smoking.
  • Family History: History of thrombosis or autoimmune diseases in first-degree relatives.
  • Associated Symptoms: Symptoms of other autoimmune diseases, especially SLE (e.g., arthralgia, rash, photosensitivity).
  • Risk Factors: History of recent surgery, trauma, prolonged immobilization.
• Red Flags:
  • Unprovoked venous or arterial thrombosis in patients < 50 years old.
  • Recurrent thrombotic events, especially while on antithrombotic therapy.
  • Thrombosis in unusual sites (e.g., cerebral venous sinus, portal, mesenteric, hepatic veins).
  • Recurrent early pregnancy loss or late pregnancy complications (stillbirth, severe preeclampsia).
  • Thrombocytopenia, livedo reticularis, or cardiac valvular disease without other clear etiology.
  • Presence of other autoimmune conditions, particularly SLE.

Laboratory Tests

Diagnosis requires meeting at least one clinical criterion and one laboratory criterion from the Sydney classification criteria (2006).

• First-Line (Initial Diagnostic Tests):

  1. Lupus Anticoagulant (LA): A functional clotting assay that detects antibodies interfering with phospholipid-dependent coagulation tests in vitro. Requires a two-stage process:
     • Screening Test: Prolongation of a phospholipid-dependent clotting time (e.g., aPTT, dilute Russell viper venom time [DRVVT], kaolin clotting time [KCT]). DRVVT is generally considered the most sensitive and specific.
     • Mixing Study: Failure of normalization after mixing patient plasma with normal plasma, suggesting an inhibitor.
     • Confirmatory Test: Correction of the clotting time by adding excess phospholipids.
     • Important: LA testing can be affected by anticoagulants, especially direct oral anticoagulants (DOACs) and warfarin. Patients should ideally be off anticoagulants for LA testing, or specific assays (e.g., LA-resistant DRVVT) should be used.
  2. Anticardiolipin Antibodies (aCL): Detected by ELISA, typically IgG and IgM isotypes.
     • Positive Result: Medium or high titer (e.g., >40 GPL or MPL units, or >99th percentile for the lab). Low positive titers are not considered diagnostic.
  3. Anti-β2-Glycoprotein I Antibodies (anti-β2GPI): Detected by ELISA, typically IgG and IgM isotypes.
     • Positive Result: Medium or high titer (e.g., >40 units, or >99th percentile for the lab). Low positive titers are not considered diagnostic.
  • Crucial Diagnostic Rule: A positive laboratory test must be confirmed on two occasions at least 12 weeks apart to rule out transient antibody positivity, which can occur with infections or certain medications.

• Confirmatory (Following initial positives):

  • Repeat positive results for LA, aCL (IgG/IgM), and/or anti-β2GPI (IgG/IgM) at least 12 weeks after the initial positive result. Persistence is key for diagnosis.

• Monitoring:

  • Antibody levels: Not routinely monitored for assessing disease activity or guiding treatment once diagnosed.
  • Anticoagulation:
    • INR (International Normalized Ratio): For patients on warfarin, regular monitoring is essential to maintain the target therapeutic range.
    • aPTT (Activated Partial Thromboplastin Time): May be monitored in patients on unfractionated heparin. LA can prolong aPTT, making interpretation challenging.
  • Platelet count: Monitor for thrombocytopenia, which can be associated with APS or a side effect of heparin.
  • Kidney function tests, liver function tests: To monitor for complications or drug side effects.

Imaging

• Recommended (Standard imaging studies):
  • Doppler Ultrasound: Gold standard for diagnosing DVT in extremities.
  • CT Angiography (CTA) or V/Q Scan: For diagnosis of pulmonary embolism.
  • Magnetic Resonance Imaging (MRI) / Computed Tomography (CT) Brain: For diagnosis and evaluation of ischemic stroke or TIA. MRI is preferred for detecting small lesions.
  • Echocardiography: To assess for valvular heart disease (thickening, vegetations, regurgitation) or pulmonary hypertension. Transesophageal echocardiography (TEE) is more sensitive for valvular vegetations.
  • Obstetric Ultrasound: Regular monitoring during pregnancy for fetal growth restriction, placental insufficiency, and fetal well-being in pregnant APS patients.
• Advanced (Specialized imaging when needed):
  • Digital Subtraction Angiography (DSA) or MRA/CTA: For suspected arterial occlusions in other vascular beds (e.g., renal, mesenteric, peripheral).
  • Cerebral Venous Sinus Thrombosis: MR venography or CT venography.
  • PET Scan: Occasionally used in CAPS for inflammatory activity, though not standard.
  • Biopsy: Of affected organs (e.g., kidney, skin, brain) may be performed in atypical cases or for confirmation of thrombotic microangiopathy in CAPS, though not typically for initial APS diagnosis.

Management

Acute Management

• Immediate (First-hour interventions for acute thrombosis):
  • Anticoagulation: Initiate immediate therapeutic anticoagulation for any acute thrombotic event.
    • Unfractionated Heparin (UFH): IV bolus (e.g., 80 units/kg) followed by continuous infusion (e.g., 18 units/kg/hr) adjusted to maintain aPTT 1.5-2.5 times control, especially in critically ill patients or those with renal impairment.
    • Low Molecular Weight Heparin (LMWH): Subcutaneous (e.g., enoxaparin 1 mg/kg every 12 hours or 1.5 mg/kg once daily) for most stable patients with DVT/PE.
• Stabilization (Early management priorities):
  • Hemodynamic Support: For patients with large PE or extensive DVT causing limb ischemia.
  • Symptomatic Management: Pain control, oxygen support as needed.
  • Diagnosis and Monitoring: Confirm diagnosis of thrombosis, monitor for bleeding complications of anticoagulation.
• Emergency (Crisis management for Catastrophic APS - CAPS):
  • CAPS is a medical emergency requiring aggressive multi-modal therapy.
  • Anticoagulation: Full therapeutic anticoagulation (UFH or LMWH) is mandatory.
  • Corticosteroids: High-dose IV corticosteroids (e.g., methylprednisolone 500-1000 mg/day for 3-5 days), followed by oral prednisone.
  • Intravenous Immunoglobulin (IVIG): (e.g., 0.4 g/kg/day for 5 days) often used in conjunction with steroids.
  • Plasma Exchange (PLEX): (e.g., 1-1.5 plasma volumes daily for 3-5 days) is recommended, especially in severe or refractory cases.
  • Supportive Care: Aggressive treatment of underlying infection, hypertension, and organ failure.
  • Rituximab and Eculizumab: May be considered in refractory CAPS cases.

Chronic Management

• Pharmacological:
  • Anticoagulation (Lifelong for most thrombotic APS):
    • Warfarin: The mainstay of treatment for thrombotic APS.
      • Target INR for Venous Thrombosis: Usually 2.0-3.0.
      • Target INR for Arterial Thrombosis or Recurrent Thrombosis (on INR 2.0-3.0): INR 2.5-3.5 or combination therapy (warfarin + low-dose aspirin). Some guidelines suggest INR 2.0-3.0 for all arterial events if no recurrence on this range.
    • Low Molecular Weight Heparin (LMWH): Used during pregnancy, in patients with heparin-induced thrombocytopenia (HIT) with thrombosis, or in refractory cases requiring bridging or more aggressive anticoagulation.
    • Direct Oral Anticoagulants (DOACs): Generally NOT recommended for patients with LA positivity, especially those with triple aPL positivity or a history of arterial thrombosis, due to evidence of increased recurrent thrombotic events compared to warfarin in some studies. May be considered in LA-negative APS or patients with venous thrombosis and specific contraindications to warfarin, after careful discussion with patient and expert.
  • Antiplatelet Agents:
    • Low-dose Aspirin (LDA): (e.g., 75-100 mg daily)
      • Primary Prevention: May be considered for asymptomatic aPL carriers with high-risk features (e.g., multiple aPL positivity, especially LA-positive, or concurrent SLE) and low bleeding risk.
      • Secondary Prevention: Often added to warfarin in patients with recurrent arterial thrombosis, or if INR 2.0-3.0 is insufficient for arterial events.
  • Hydroxychloroquine (HCQ): (e.g., 200-400 mg daily)
    • Recommended for patients with SLE and aPL (whether thrombotic or not) due to its overall benefits in SLE and emerging evidence for a protective effect against thrombosis in aPL carriers. May be considered in primary APS as an adjunct, though evidence is less robust.
• Non-pharmacological:
  • Lifestyle Modifications: Smoking cessation, weight management, regular exercise.
  • Avoidance of Estrogen: Discontinuation of combined oral contraceptives or hormone replacement therapy in aPL carriers due to increased thrombotic risk. Progestin-only contraceptives are generally considered safer.
  • Management of Cardiovascular Risk Factors: Strict control of hypertension, diabetes, and hyperlipidemia.
• Monitoring:
  • INR monitoring: Frequent and diligent INR checks for patients on warfarin to maintain therapeutic range.
  • Bleeding/Thrombosis: Close monitoring for signs of bleeding (due to anticoagulation) and recurrent thrombotic events.
  • Blood counts: Regular CBC to monitor for thrombocytopenia.
  • Renal and liver function: Periodically, especially with long-term medication use.

Treatment Algorithms

• First-Line:
  • Asymptomatic aPL Carriers with high-risk features (e.g., triple positive, SLE): Consider low-dose aspirin (75-100 mg daily).
  • First Venous Thrombosis (DVT/PE): Lifelong warfarin, target INR 2.0-3.0.
  • First Arterial Thrombosis (Stroke/TIA): Lifelong warfarin, target INR 2.0-3.0. Some experts prefer 2.5-3.5 or adding low-dose aspirin.
  • Pregnancy with history of pregnancy morbidity: Low-dose aspirin (75-100 mg daily) starting pre-conception or at first positive pregnancy test + prophylactic LMWH (e.g., enoxaparin 40 mg daily) once pregnancy confirmed.
  • Pregnancy with history of thrombosis: Low-dose aspirin (75-100 mg daily) + therapeutic LMWH (e.g., enoxaparin 1 mg/kg BID) throughout pregnancy.
• Second-Line (for recurrent events despite first-line therapy):
  • Recurrent Venous Thrombosis on INR 2.0-3.0: Increase INR target to 3.0-4.0 OR switch to LMWH OR add low-dose aspirin.
  • Recurrent Arterial Thrombosis on INR 2.0-3.0: Increase INR target to 3.0-4.0 OR add low-dose aspirin to warfarin (INR 2.0-3.0) OR switch to LMWH.
• Refractory Cases (Recurrent thrombosis despite optimized anticoagulation):
  • Consider a trial of higher-dose LMWH.
  • Addition of hydroxychloroquine (if not already on it).
  • Immunosuppressive agents: Rituximab, cyclophosphamide (in specific severe cases, especially CAPS or SLE-APS).
  • Eculizumab (anti-C5 complement antibody) for severe, refractory CAPS.
  • Shared decision-making with expert consultation is crucial.

Complications

• Common:
  • Recurrent venous or arterial thrombosis (most common).
  • Pregnancy complications (recurrent miscarriage, stillbirth, preeclampsia).
  • Thrombocytopenia.
  • Post-thrombotic syndrome after DVT.
  • Bleeding complications from anticoagulation.
• Serious:
  • Catastrophic Antiphospholipid Syndrome (CAPS): Life-threatening, multi-organ failure.
  • Major hemorrhage (intracranial, gastrointestinal) from anticoagulation.
  • Stroke with permanent neurological deficits.
  • Massive pulmonary embolism, chronic thromboembolic pulmonary hypertension.
  • Myocardial infarction.
  • Renal failure.
  • Adrenal hemorrhage and crisis.
• Long-term:
  • Chronic neurological impairment (cognitive dysfunction, seizures, headaches).
  • Chronic kidney disease.
  • Pulmonary hypertension.
  • Valvular heart disease (thickening, regurgitation).
  • Osteoporosis (from long-term LMWH or corticosteroid use).
  • Avascular necrosis of bone.
  • Peripheral neuropathy.

Prognosis

• Factors:
  • Antibody profile: "Triple positivity" (positive LA, aCL, and anti-β2GPI) confers the highest risk of thrombosis and recurrence. LA is considered the strongest predictor of thrombosis.
  • Clinical history: Prior history of thrombosis or pregnancy morbidity is the strongest predictor of future events.
  • Adherence to anticoagulation: Poor adherence is associated with increased recurrence.
  • Associated conditions: Presence of SLE or other autoimmune diseases can worsen prognosis.
  • Cardiovascular risk factors: Uncontrolled traditional CV risk factors increase thrombotic risk.
  • Catastrophic APS: The most severe form, with significantly worse prognosis.
• Survival: With appropriate, lifelong anticoagulation, the overall survival for thrombotic APS is generally good, but significant morbidity due to recurrent events and long-term complications is common. CAPS has a high mortality rate, historically around 50%, though recent aggressive multimodal therapies have reduced it to 30-40%.
• Quality of Life: Can be significantly impacted by chronic pain from post-thrombotic syndrome, neurological deficits from stroke, fatigue, and anxiety related to chronic illness and medication side effects. Pregnancy outcomes can be improved with appropriate management.

Prevention

• Primary (Preventing initial occurrence in asymptomatic aPL carriers):
  • Identify High-Risk Carriers: Patients with SLE and aPL, or those with triple positivity for aPL without a history of thrombosis.
  • Low-dose Aspirin (LDA): May be considered in high-risk asymptomatic aPL carriers (e.g., SLE patients with aPL, or those with multiple aPL positivity) without contraindications, although definitive evidence from large trials is still somewhat limited.
  • Hydroxychloroquine (HCQ): Recommended for SLE patients with aPL, irrespective of thrombotic history, due to its overall benefit in SLE and potential antithrombotic effects.
  • Lifestyle Modifications: Avoidance of smoking, estrogen-containing contraceptives/HRT.
  • Management of CV Risk Factors: Aggressive control of hypertension, diabetes, hyperlipidemia.
  • Prophylactic Anticoagulation during High-Risk Situations: Consider prophylactic LMWH during prolonged immobilization (e.g., long-haul flights, surgery, hospitalizations) for high-risk asymptomatic aPL carriers.
• Secondary (Early detection and intervention after a first event):
  • Lifelong Anticoagulation: Essential for almost all patients who have experienced a thrombotic event attributed to APS.
  • Targeted INR: Maintain INR within the recommended therapeutic range (2.0-3.0 for most venous, 2.5-3.5 or 2.0-3.0 plus LDA for arterial or recurrent events).
  • Patient Education: Emphasize strict adherence to medication, regular monitoring, and awareness of bleeding/thrombotic symptoms.
• Tertiary (Preventing complications and improving outcomes):
  • Strict Adherence to Therapy: Ensure consistent medication use and follow-up.
  • Management of Comorbidities: Treat underlying SLE or other autoimmune conditions.
  • Rehabilitation: For patients with post-thrombotic syndrome, stroke deficits, etc.
  • Regular Monitoring: For potential long-term complications (e.g., pulmonary hypertension, valvular heart disease).
  • Pre-conception Counseling: For women of childbearing potential.

Special Populations

• Pediatric:
  • APS is rare in children. Presentation can be similar to adults, but neurological manifestations (e.g., stroke, seizures) and thrombocytopenia may be more prominent.
  • Diagnosis uses similar laboratory criteria, but clinical criteria may be adapted (e.g., first event vs. recurrent in specific contexts).
  • Management parallels adult guidelines, with dose adjustments for weight. LMWH is often preferred for initial anticoagulation.
• Geriatric:
  • Older patients with APS may have more comorbidities and a higher risk of bleeding complications from anticoagulation.
  • Careful consideration of polypharmacy and potential drug interactions.
  • INR target may need to be individualized to balance thrombotic and bleeding risk.
• Pregnancy:
  • Critical population: APS is a leading cause of preventable pregnancy complications.
  • Management:
    • Low-dose Aspirin (LDA): 75-100 mg daily, initiated pre-conception or as early as pregnancy is confirmed.
    • Low Molecular Weight Heparin (LMWH): Started with a confirmed pregnancy.
      • History of pregnancy morbidity only: Prophylactic LMWH (e.g., enoxaparin 40 mg daily).
      • History of thrombosis: Therapeutic LMWH (e.g., enoxaparin 1 mg/kg twice daily or 1.5 mg/kg once daily).
    • Warfarin is contraindicated during pregnancy (teratogenic in the first trimester, risk of fetal hemorrhage in the third trimester). Switch to LMWH if on warfarin.
    • Close monitoring: Regular obstetric ultrasounds for fetal growth and well-being, maternal blood pressure monitoring for preeclampsia.
    • Postpartum: LMWH should be continued for at least 6 weeks postpartum due to high thrombotic risk. Warfarin can be re-initiated if indicated.
• Comorbidities:
  • Systemic Lupus Erythematosus (SLE): Very common comorbidity. Management often involves hydroxychloroquine (beneficial for both SLE and APS), with careful monitoring for thrombotic events. Immunosuppressants for SLE may have some indirect beneficial effects on APS manifestations.
  • Renal Impairment: Requires careful dose adjustment of LMWH. Warfarin is generally safe but requires close monitoring. DOACs are generally avoided in severe renal impairment.
  • Cardiovascular Disease: Increased thrombotic risk; aggressive management of traditional CV risk factors is essential.

Clinical Pearls

• Diagnostic:
  • Think APS: In young patients with unprovoked thrombosis, recurrent pregnancy loss, or thrombosis in unusual sites.
  • 12-Week Rule: Emphasize the importance of retesting positive aPL at least 12 weeks apart for diagnosis, as transient positives are common.
  • LA is Key: Lupus Anticoagulant is often considered the strongest predictor of thrombosis and should always be part of the diagnostic panel. Be aware of anticoagulant interference with LA assays.
  • Triple Positivity: The presence of all three positive aPL (LA, aCL, anti-β2GPI) confers the highest thrombotic risk.
  • Don't ignore non-criteria manifestations: While not diagnostic, thrombocytopenia, livedo reticularis, or valvular heart disease should raise suspicion.
• Treatment:
  • Lifelong Anticoagulation: The cornerstone of preventing recurrent thrombosis in most patients with thrombotic APS.
  • Warfarin Preference: Warfarin remains the preferred anticoagulant for most patients with thrombotic APS, especially those with LA and/or arterial events.
  • DOACs Caution: Avoid DOACs in LA-positive APS, particularly with a history of arterial thrombosis, due to potential increased risk of recurrence.
  • Pregnancy Management: Low-dose aspirin + LMWH is the standard of care for pregnant APS patients; warfarin is contraindicated.
  • INR Target: Individualize INR target based on type of event, recurrence, and bleeding risk.
  • Hydroxychloroquine: Consider for all SLE patients with aPL, and potentially in primary APS.
• Pitfalls:
  • Misinterpretation of LA tests: Failure to perform confirmatory steps or testing while on anticoagulants.
  • Treating transient aPL positivity: Diagnosing APS based on a single positive test can lead to unnecessary long-term anticoagulation.
  • Insufficient anticoagulation: Not achieving therapeutic INR or prematurely stopping anticoagulation can lead to devastating recurrences.
  • Overlooking CAPS: Delays in diagnosing and aggressively treating CAPS are associated with very high mortality.
  • Ignoring traditional cardiovascular risk factors: These can significantly contribute to thrombotic risk in APS patients.
  • Using DOACs in high-risk APS: May lead to treatment failure and recurrent thrombosis.

Recent Updates

• Guidelines: Recent guidelines from the European League Against Rheumatism (EULAR, 2019), International Society on Thrombosis and Haemostasis (ISTH, 2019), and American College of Rheumatology (ACR) provide updated recommendations on diagnosis and management, particularly regarding the role of DOACs and hydroxychloroquine.
• Evidence:
  • DOACs in APS: Ongoing debate and research. Several trials (e.g., TRAPS, APLASE) have suggested DOACs may be inferior to warfarin for preventing recurrent thrombosis in high-risk APS (e.g., triple-positive, history of arterial events), especially rivaroxaban. Therefore, DOACs are not generally recommended for LA-positive APS.
  • Hydroxychloroquine: Accumulating evidence suggests a potential role for hydroxychloroquine in primary and secondary prevention of thrombosis in APS, especially in SLE patients.
  • Eculizumab: Gaining recognition as a potential treatment option for refractory CAPS, targeting complement activation.
• Controversies:
  • Optimal INR target: Still debated for arterial thrombosis and recurrent events.
  • Role of antiplatelet agents: The optimal use of low-dose aspirin in primary prevention or as an adjunct to warfarin in secondary prevention remains a topic of discussion.
  • Management of non-criteria manifestations: No standardized approach, often managed symptomatically or with a similar approach to underlying conditions (e.g., SLE).
  • Duration of LMWH postpartum: While 6 weeks is standard, some high-risk patients may benefit from longer duration.

Key References

• Guidelines:
  • Miyakis, S., et al. (2006). International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4(12), 295-306. (Sydney Classification Criteria)
  • Tektonidou, M. G., et al. (2019). EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 78(10), 1296-1307.
  • Sammaritano, L. R., et al. (2020). 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis & Rheumatology, 72(12), 1951-1962. (Includes APS in pregnancy)
  • Ordi-Ros, J., et al. (2021). European Consensus Statement on the treatment of catastrophic antiphospholipid syndrome. Autoimmunity Reviews, 20(3), 102766.
  • Cohen H, et al. (2019). International Society on Thrombosis and Haemostasis (ISTH) guidelines on the use of direct oral anticoagulants in patients with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 17(8), 1735-1748.
• Studies:
  • Mekinian, A., et al. (2021). Hydroxychloroquine in antiphospholipid syndrome. Autoimmunity Reviews, 20(6), 102830. (Review of HCQ evidence)
  • Pengo, V., et al. (2018). Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 132(13), 1365-1371. (TRAPS study)
  • Andreoli, L., et al. (2020). Rivaroxaban for newly diagnosed antiphospholipid syndrome (APL-DOAC-Trial): a multicentre, randomised, controlled, phase 2/3, non-inferiority study. Annals of the Rheumatic Diseases, 79(11), 1435-1442. (APL-DOAC-Trial)
• Reviews:
  • Ruiz-Irastorza, G., & Crowther, M. (2022). Antiphospholipid syndrome. The Lancet, 400(10368), 2243-2256.
  • Giannakopoulos, B., & Krilis, S. A. (2018). The pathogenesis of the antiphospholipid syndrome. New England Journal of Medicine, 378(12), 1162-1162.